The AstraZeneca trial is allowed to resume
Federal health regulators have decided to allow the resumption of U.S. studies of a leading Covid-19 vaccine candidate from AstraZeneca PLC and the University of Oxford, according to a person familiar with the matter and materials reviewed by The Wall Street Journal.
Here is the WSJ article, no real explanation given by either the company or the FDA.